Kornimate/medical-research-clean huggingface dataset:
a biobehavioral intervention for young men with testicular cancer

Conditions: Testis Cancer

Summary: this study is a randomized controlled biobehavioral pilot trial designed to investigate the feasibility and preliminary efficacy of a novel intervention, goal-focused emotion-regulation therapy (get) aimed at improving distress symptoms, emotion regulation, goal navigation skills, and stress-sensitive biomarkers in young adult testicular cancer patients. participants will be randomized to receive six sessions of get or individual supportive therapy (isp) delivered over eight weeks. in addition to indicators of intervention feasibility, the investigators will measure primary (depressive and anxiety symptoms) and secondary (emotion regulation and goal navigation skills, career confusion) psychological outcomes prior to (t0), immediately after (t1) and twelve weeks after intervention at t2. additionally, identified biomarkers will be measured at baseline and at t2.


Eligibility criteria:
inclusion criteria: * between the ages of 18 and 39 years at the time of consent * confirmed diagnosis of testis cancer (any stage) * completed chemotherapy for testis cancer within 2 years prior to consent * fluency in english (per self-report) * sub-optimal self-regulation as evidenced by a score of 1.8 or below on the goal navigation scale or a score of 4 or greater on the distress thermometer (dt) exclusion criteria: * lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder (per self-report) * active suicide plan * disorder that compromises comprehension of assessments or informed consent information * self-reported medical condition or medication use known to confound measures of systemic inflammation * daily smoking
impact of computerized glove on facilitating hand function recovery and neural plasticity in stroke

Conditions: Stroke

Summary: hand impairment post-stroke is a common condition that contributes to disability around the world. an effective intervention is required to optimize functional outcomes in the rehabilitation of hand-in-stroke patients.

thirty male/female stroke patients in the sub-acute phase were randomly assigned in to the two groups (study and control) in sets of three. the study group (a) (n = 15) underwent a hand rehabilitation program using the computerized glove combined with the selected hand program. the control group (b) (n = 15) received only the selected hand program. the treatment schedules for 18 consecutive treatment sessions, three times per week.

Eligibility criteria:
inclusion criteria: 1. the patient's age ranges from 45 to 65 years old with a minimum score of 24 points on the mini mental test. 2. duration of illness ranges from (6weeks to 6 months) after stroke onset. 3. first stroke. 4. upper limb spasticity ranged from 1+ to 2 according to the modified ashworth scale. 5. with a minimum 10° extension and/or flexion of the wrist or fingers, an ability to flex and extend the wrist joint five times continuously without losing active range of motion. exclusion criteria: patients with the following 1. apraxia or hemianopsia. 2. diabetic polyneuropathy. 3. aphasia , cognitive deficits. 4. a previous disability in the upper limbs, tactile agnosia (stereognosis). 5. lt hemiplegia, post botox injection, recurrent stroke, and posterior parietal lesion.

Keywords: stroke hand recovery plasticity computerized glove
liquid biopsy collection study

Conditions: Chaperonin-Containing TCP-1; Circulating Tumor Cells; CCT; CTC

Summary: the purpose of this study is to develop a liquid biopsy approach for detection of circulating tumor cells (ctc) that could be used in place of the more invasive and potentially risky methods of tissue biopsy. the aims of the project are: (a) determine whether the chaperonin-containing tcp-1 (cct) chaperonin can used to identify rare cancer cells in blood, and (b) establish whether the cancer cells detected using the cct chaperonin for identification have invasive or metastatic potential.


Eligibility criteria:
inclusion criteria: * male or female * age greater than or equal to 18 and less than or equal to 80 years. exclusion criteria: * adults unable to give informed consent * individuals who are not yet adults (infants, children, teenagers; under the age of 18) * individuals who weigh less than 110 lbs (as standard clinically advised to not give blood) * pregnant women (due to hormonal changes in blood) * prisoners * persons reporting a current microbial (bacterial, viral, or fungal) infections * persons reporting that they are current taking antibiotic medications * persons with body temperatures above 99of (indicating a fever)

Keywords: healthy
wearable evaluation of ambulatory readings for blood pressure

Conditions: Normal Blood Pressure; Controlled Hypertension; Uncontrolled Hypertension

Summary: the purpose of this project is to compare the performance and validity of novel wearable technologies that measure blood pressure (bp) and physical activity with a spacelabs ambulatory blood pressure monitoring (abpm) device.

the investigators will recruit community-dwelling participants to wear novel cuffless bp monitoring devices for comparison with a spacelabs abpm device throughout a 24-hour period. the identification of accurate cuffless bp technologies would greatly improve access to abpm and allow for bp measurements at times when the use of cuff-based devices are not feasible. knowledge from this project will inform subsequent research protocols among adults and under-represented groups. up to 250 participants (at least 100) will be involved in this study each wearing up to 7 devices (6 bp devices and 1 activity monitor). the assignment of devices will be randomized by day and by the arm or wrist on which they are worn. during the first visit, participants will provide their consent and be randomly fitted with 3 bp devices; either the spacelabs abpm device or the abpmpro device, the aktiia wristband bp monitor, and one of two other cuff-based wrist bp monitors, along with an activity monitor to track body positions. these devices will be worn continuously for at least 24-hours, including overnight, before being returned. on the following day, for visit 2, participants will be fitted with a different set of 3 bp devices; the abpmpro device or spacelabs abpm device, the aktiia wristband bp device (on the opposite wrist from the previous day), and the final cuff-based wristband bp device. additionally, participants will wear an ambulatory bp device as a patch on the chest. these devices will also be worn for at least 24 hours. this study will enable characterization of the feasibility, practicality, and effectiveness of the measurements and the devices\&#39; accuracy and precision.

Eligibility criteria:
inclusion criteria: * age 18 to 100 years * all neighborhoods in boston area * be able to walk with two limbs and have two arms * willing and able to complete required measurement procedures * able to provide informed consent exclusion criteria: * failure to receive informed consent * arm circumference of more than 50cm

Keywords: cuff-based bp device cuffless bp device abpm blood pressure hypertension
a nis of alpelisib in combination with fulvestrant in postmenopausal women, and men, with hr+,her2- , locally advanced or metastatic breast cancer with a pik3ca mutation, after disease progression following endocrine therapy as monotherapy, in the real-world setting

Conditions: Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation

Summary: this is a prospective, multi-national, non-interventional study (nis) collecting data from postmenopausal women, and adult men, with hr+, her2- locally advanced or metastatic breast cancer whose tumor harbors a pik3ca mutation, and who are treated with alpelisib in combination with fulvestrant after disease progression following endocrine therapy as monotherapy, in the real-world setting.

once the patient provides informed consent, he or she is enrolled in the study. patients will be followed from enrollment until 1) 30 days after alpelisib treatment discontinuation, or 2) death, or 3) lost to follow-up, or 4) patient withdrawal, or 5) physician decision to end treatment/study, or 6) end of the study, whichever occurs first. the end of the study is defined as a maximum of 12 months after the date the last patient was enrolled (lpfv); if the last patient is still on treatment on that date, they will not be followed up any further

Eligibility criteria:
inclusion criteria: * signed informed consent from the patient or a legally acceptable representative, obtained before any study-related activities are undertaken * patients diagnosed with hr+, her2- locally advanced or metastatic breast cancer with a pik3ca mutation * patients who have disease progression following endocrine therapy as monotherapy * patients must be postmenopausal women, or men, ≥18 years of age * patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant exclusion criteria: * use of alpelisib prior to signing the informed consent form for this study * participation in an interventional study within 30 days prior to the initiation of alpelisib

Keywords: breast cancer non-interventional study nis alpelisib fulvestrant pass
arena - project atrial fibrilation rhine-neckar region

Conditions: Atrial Fibrillation

Summary: arena aims to inform patients about the symptoms and the risks of atrial fibrilation. the study design includes three study arms: 1. arena intervention: this project will examine the effectiveness of population education. 2. arena medication: the aim is to examine the patient's adherence and to analyze whether there are any complications. 3. arena migration: arena migration aims to examine whether a targeted population education can improve the care of people with a turkish migration background.

arena aims to inform patients about the symptoms and the risks of atrial fibrilation. the study design includes three study arms: 1. arena intervention: this project will examine the effectiveness of population education and other measures to provide care for patients with atrial fibrillation. in the end of the control phase (1 year recruitment of approximately 10,000 patients), there will be a wide publicity, informing about the disease. 2. arena medication: arena records the patient's complete medication at all survey times (up to two weeks after recruitment and follow up). this allows an accurate assessment of interactions between individual substances. in addition, attempts are being made to determine drug concentrations of anticoagulants directly by the blood of the patient. therefore, patients are provided with kits, which they can use to apply a drop of blood from your fingertip to a filter paper. the aim is to examine the patient's adherence and to analyze whether there are any complications. 3. arena migration: the metropolregion rhein-neckar is characterized by a high proportion of people with a turkish migration background. arena migration aims to examine whether a targeted population education can improve the care of this patient group.

Eligibility criteria:
inclusion criteria: * willingness to participate * atiral fibrilation * 18 years or older exclusion criteria: * not willing to participate
natural history clinical study in adult pku

Conditions: Phenylketonurias; PKU

Summary: the objective of this study is to characterize the natural history of phenylketonuria (pku) due to phenylalanine hydroxylase (pah) deficiency in adults through prospective collection of clinical, cognitive, and quality of life assessments.

phenylalanine hydroxylase (pah) deficiency is a rare disease caused by an inborn error of metabolism. if left untreated, pah deficiency results in progressive, irreversible neurological impairment during infancy and early childhood. this study is designed to collect information about important pku-related symptoms and tests to characterize the natural history of pku due to pah deficiency in a selected sample of adults. no new investigational treatment will be administered to participating patients.

Eligibility criteria:
key inclusion criteria: * aged 18-55 years at the time of informed consent * diagnosis of pku due to pah deficiency * one plasma phe value with a concentration of ≥ 600 μmol/l drawn at screening and at least 1 historical phe value ≥ 600 μmol/l in the preceding 12 months key exclusion criteria: * subjects with pku that is not due to pah deficiency * alanine aminotransferase (alt) \> 1.5x upper limit of normal (uln) and aspartate aminotransferase (ast) \>1.5x uln * alkaline phosphatase \> 1.5x uln * total bilirubin \> 1.5x uln, direct bilirubin ≥ 1.5x uln, unless associated with gilbert's syndrome. * serum creatinine \> 1.5x uln * hematology values outside of the normal range (hemoglobin \< 11.0 g/dl for males or \< 10.0 g/dl for females; white blood cells (wbc) \< 3,000/μl; absolute neutrophils \< 1,500/μl; platelets \< 100,000/μl) * hemoglobin a1c \> 6.5% or fasting glucose \> 126 mg/dl * any clinically significant abnormal laboratory result at screening, as determined by the investigator
effect of digital combined decongestive therapy in patients with breast cancer-related lymphedema: a follow-up study

Conditions: Breast Cancer-Related Lymphedema

Summary: this study investigated the short- and long-term effects of digital combined decongestive therapy in breast cancer-related lymphedema. limb volume and quality of life (lymph-icf) were assessed at baseline, post-treatment, and 12-week follow-up.

this study evaluated the feasibility and effectiveness of a digital combined decongestive therapy (cdt) program in patients with breast cancer-related lymphedema. after an initial face-to-face training session on self-bandaging, self-manual lymphatic drainage, breathing exercises, and skin care, patients followed a 4-week digital cdt program with remote guidance. compression garments were used during the maintenance phase. limb volume was measured using circumference method. quality of life was assessed with the lymph-icf questionnaire. assessments were repeated post-treatment and at 12-week follow-up.

Eligibility criteria:
inclusion criteria: * diagnosed with breast cancer-related lymphedema (bcrl) within the last 6 to 60 months. * voluntarily agreed to participate in the study. exclusion criteria: * presence of active infection. * history of bilateral breast surgery. * severe breast cancer-related lymphedema.

Keywords: breast cancer-related lymphedema combined decongestive therapy digital therapy
assess measurements of wireless cardiac output device

Conditions: Congestive Heart Failure

Summary: heart failure is a common cardiovascular problem which is increasing in both prevalence and incidence and associated with substantial morbidity and mortality. the management of heart failure patients is complex and has become a priority world over. effective methods to keep heart failure patients out of the hospital are essential, both in the interests of the patient's health, as well as to reduce the burden on the health care system

heart failure patients should be in a position to provide readings of their weight, blood pressure, fluid intake, thoracic fluid, heart rate, heart rate variability, respiration rate, stroke volume, cardiac output, medications and other important parameters and communicate this data to care providers using wireless technology. this data should be made available to medical personnel regularly and on a periodic basis. in this manner the health care providers can detect and respond to warning signs or alerts before the patient's condition worsens to warrant a visit to the doctor or a hospital admission with features of heart failure decompensation. programs for chronic heart failure that include remote monitoring have been shown to have a positive effect on clinical outcomes in community dwelling patients with chronic heart failure. in preparation for a study evaluating the effectiveness of mobile monitoring, the value of stroke volume and cardiac output need to be validated against fda approved devices that are available in a hospital or clinic setting. this study covers the validation of the measurements taken with the proposed home monitoring device, perminova's covatm sensor (sensor) against clinic devices such as bio-impedance devices, echocardiogram, doppler and/or mri

Eligibility criteria:
inclusion criteria: * subjects of either gender above the age of 18 years * the subject is able and willing to provide written informed consent prior to enrollment in the study * one or more of the following diagnosis * new york heart association (nyha) classification class of i-iv or stages a-d * symptoms of dyspnea * chronic renal failure on renal replacement therapy exclusion criteria: * patients who may not come for follow up or likely to drop out of the study * any illness which may preclude regular follow up * patient is unable or not willing to wear electrode patches as required * patient has skin sensitivity to adhesive or hydrogel materials used in electrode patches * patient is considered by the pi to be medically unsuitable for study participation

Keywords: mhealth, hypertension, atherosclerotic disease, diabetes, obesity, metabolic syndrome, cardiotoxins, cardiomyopathy, dsypnea
osteoporotic precisely screening using chest radiograph and artificial neural network (opscan)

Conditions: Osteoporosis; Osteoporotic Fractures

Summary: artificial intelligence-assisted diagnosis and prognostication in osteoporosis using chest x-ray


Eligibility criteria:
inclusion criteria: * patients recieved at least 1 chest x-ray examination in 2022 * more than 66% chest x-ray identified as high risk of osteoporosis by ai-cxr exclusion criteria: * patients with history of at least 1 dual energy x-ray absorptiometry (dxa) * patients with history of osteoporosis or osteoportic fracture * patients recieved prescription anti-osteoporotic treatment (excluding vitamin d or calcium) * patients died before 01 jan 2023
usefulness of a prothetic absorbable mesh in incisional hernia prevention after midline laparotomy

Conditions: Incisional Hernia

Summary: background: development of an incisional hernia is one of the most frequent complications of midline laparotomies requiring reoperation. this paper presents the rationale, design, and study protocol for a randomized controlled trial, the aim of which was to evaluate the efficacy and safety of prophylactically placing a bioabsorbable synthetic mesh for reinforcement of a midline fascial closure. methods: the prebious trial (preventive midline laparotomy closure with a bioabsorbable mesh) is a multicenter randomized controlled trial in which adult patients undergoing elective or urgent open abdominal operations through a midline laparotomy incision are assigned to one of two groups based on the laparotomy closure procedure: an intervention group in which a continuous polydioxanone (pds) suture is reinforced with a commercially available gore® bio-a® tissue reinforcement prosthesis (w. l. gore \& associates, flagstaff, arizona, usa), or a control group with continuous pds suture only. both groups are followed over 6 months. outcomes: the primary outcome is the appearance of incisional hernias assessed by physical examination at clinical visits and radiologically (ct scan) performed at the end of follow-up. secondary outcomes are the rate of complications, mainly infection, hematoma, burst abdomen, pain, and reoperation. the prebious trial has the potential to demonstrate that suture plus prosthetic mesh insertion for routine midline laparotomy closure is effective in preventing incisional hernias after open abdominal surgery, to avoid the effects on those affected, such as poor cosmesis, social embarrassment, or impaired quality of life, and to save costs potentially associated with incisional hernia surgical repair.


Eligibility criteria:
inclusion criteria: * adults aged 18 years or older, * signed informed consent, * patients undergoing elective or urgent open abdominal surgical procedures regardless of benign or malignant disease. exclusion criteria: * presence of primary or recurrent incisional hernia * expected survival \< 12 months.

Keywords: incisional hernia prevention laparotomy closure absorbable mesh
acupoint transcutaneous electrical nerve stimulation in hospitalized copd patients with severe dyspnoea

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: introduction: chronic obstructive pulmonary disease (copd) presents with a gradual reduction and little bitterness reversible airflow causing shortness of breath, chronic cough and sputum abnormal. patients with copd often suffer exacerbations of their symptoms, particularly dyspnea, causing hospital admissions. recent studies have shown that acupuncture stimulation transcutánea (acutens) dingchuan point (ex-b1) could help reduce dyspnea in patients with copd. objective: the aim of this study was to evaluate the possible utility of adding to the usual treatment stimulation acutens in copd patients admitted with severe dyspnea. methodology: patients who agree to participate will be randomly divided into two groups. the intervention group will receive a daily treatment, during the period of hospitalization, 45 minutes stimulation at acupuncture point acutens dingchuan (ex-b1), while the control group performed the same procedure with a device tens simulated. the extent of dyspnea in both groups as well as the number of days of hospitalization and the number of drugs consumed.


Eligibility criteria:
inclusion criteria: 1. patients aged between 45 and 70 years, with a diagnose of copd according to the gold guidelines. 2. patients with one episode of hospitalization for copd exacerbation in the past year, but not more than three episodes. 3. smoking habit history of more than 10 packages-year. 4. patients able to correctly understand and answer the modified borg scale. 5. patiens with an initial degree of dyspnoea with a score of at least 5 in the modified borg scale. 6. patients recruited for the study during the first 48 hours of their hospitalization. 7. patients who accept to participate in the study and sign the informed consent. exclusion criteria: 1. patients with any contraindication for transcutaneous electrical stimulation (patiens with pacemakers, skin injury in the application area ...). 2. patiens with any cardiovascular, neurological or psychiatric disease that may affect the perception of dyspnea.

Keywords: acupuncture tens physiotherapy